Method for curing polymer composition in contact with medical substrate

The polymer composition with a specific copolymer and hydrophilic (meth)acrylate monomer, applied to medical substrates and contacted with a water medium, addresses the challenges of adhesive strength and safety in medical adhesives, achieving rapid and effective bonding without heat or light, suitable for wet medical substrates.

WO2024237321A1PCT designated stage expired Publication Date: 2024-11-21TOYOBO CO LTD

Patent Information

Application Number
PCT/JP2024/018198
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-18
Filing Date
2024-05-16
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Medical adhesives face challenges in achieving high adhesive properties in wet conditions, rapid curing without heat or light, ease of operation, and safety concerns such as low adhesive strength, toxicity, and brittleness, particularly with fibrin glue and cyanoacrylate adhesives.

Method used

A polymer composition containing a solvent and a copolymer with a monomer represented by formula (1) and a (meth)acrylate monomer having a hydrophilic group is applied to a medical substrate, and a water-containing medium is brought into contact to form a cured polymer composition layer, avoiding heating or irradiation.

Benefits of technology

The method provides high adhesion to wet medical substrates without adverse effects, ensuring rapid curing and improved safety, with the polymer composition exhibiting strong bonding and flexibility suitable for soft tissues.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024018198_21112024_PF_FP_ABST
    Figure JP2024018198_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides a method for curing a polymer composition having high adhesion to a medical substrate, especially to a wet medical substrate, without involving heating or irradiation with actinic rays, which may adversely affect the medical substrate. Specifically, the present invention provides a method for curing a polymer composition, the method comprising: a step in which a polymer composition containing a solvent and a copolymer that has, as constituent components, a monomer represented by formula (1) and a (meth)acrylate monomer having a hydrophilic group is applied to a medical substrate to form a polymer composition layer; and a step in which a water-containing medium is brought into contact with the polymer composition layer to form a polymer composition cured layer.
Need to check novelty before this filing date? Find Prior Art

Description

Method for curing polymer compositions in contact with medical substrates - Patent Application 20070122997

[0001] The present invention relates to a method for curing a polymeric composition in contact with a medical substrate.

[0002] Medical adhesives require high adhesiveness in wet conditions. Furthermore, for practical use, they must cure quickly, be cured by a method other than heat or light, and be easy to use. Fibrin glue, a commonly used medical adhesive, cures in approximately one minute after solution mixing, but requires proper mixing of two liquids (fibrinogen and thrombin), making it difficult to use. Furthermore, it suffers from issues such as low adhesive strength and concerns about viral infection. Cyanoacrylate adhesives cure within seconds to minutes upon reaction with water, but they cure by reacting with moisture in the air before coming into contact with tissue, requiring careful handling. Furthermore, they suffer from issues such as the generation of toxic formaldehyde upon hydrolysis, brittleness of the cured product, and poor flexibility that prevents them from conforming to soft tissue. Therefore, new medical adhesives that meet these requirements are needed.

[0003] Patent Document 1 discloses a medical adhesive that uses dextran aldehyde and poly-L-lysine. This adhesive cures quickly, within one to several seconds, by mixing the two components. However, because it is a two-component system, it is difficult to use.

[0004] Japanese Patent No. 4092512

[0005] Under these circumstances, an object of the present invention is to provide a method for curing a polymer composition that has high adhesion to a medical substrate, particularly to a medical substrate in a wet state, without involving heating or irradiation with actinic rays, which may have adverse effects on the medical substrate.

[0006] As a result of extensive research into the present invention, the inventors have found that the above-mentioned problems can be solved by bringing a water-containing medium into contact with a polymer composition layer containing a solvent and a copolymer containing, as constituent components, a monomer represented by the following formula (1) and a (meth)acrylate monomer having a hydrophilic group, and have thus completed the present invention.

[0007] The present invention includes, for example, the subject matter described in the following items: [1] A method for curing a polymer composition, comprising: applying a polymer composition containing a solvent and a copolymerized polymer having, as constituent components, a monomer represented by the following formula (1) and a (meth)acrylate monomer having a hydrophilic group, to a medical substrate to form a polymer composition layer; and contacting the polymer composition layer with a water-containing medium to form a cured polymer composition layer. (In the formula, R 1 represents a hydrogen atom or a methyl group, L represents an amide bond, an ester bond or a direct bond, x represents 0 or an integer of 1 to 10, and y represents an integer of 1 to 5.

[0008] The present invention can provide a method for curing a polymer composition having high adhesiveness to a medical substrate, particularly to a medical substrate in a wet state, typically to a biological tissue in a wet state, without involving heating or irradiation with actinic rays, which may adversely affect the medical substrate.

[0009] FIG. 1 is a schematic illustration of the evaluation of the cure of a polymer composition.

[0010] The present invention will be described in detail below. However, the present invention is not limited to the embodiments described below. Furthermore, (meth)acrylate refers to methacrylate and acrylate, and (meth)acrylic refers to methacrylic and acrylic.

[0011] The method for curing a polymer composition of the present invention is a method for curing a polymer composition, comprising the steps of applying a copolymerized polymer composition containing a solvent and a copolymerized polymer having, as constituent components, a monomer represented by the following formula (1) and a (meth)acrylate monomer having a hydrophilic group, to a medical substrate to form a polymer composition layer, and bringing the polymer composition layer into contact with a water-containing medium to form a cured polymer composition layer.

[0012] In formula (1), R 1represents a hydrogen atom or a methyl group, and L represents an amide bond, an ester bond, or a direct bond. x represents 0 or an integer of 1 to 10, preferably 0 or an integer of 1 to 5, and more preferably 0 or an integer of 1 to 3. y represents an integer of 1 to 5, preferably an integer of 1 to 3, more preferably 2 or 3, and even more preferably 2.

[0013] The monomer represented by formula (1) is preferably a monomer represented by the following formula (1a): (In the formula, each symbol is the same as defined above.)

[0014] When L is an amide bond, the monomer represented by formula (1) is preferably (meth)acrylamide. Examples thereof include N-[2-(3,4-dihydroxyphenyl)methyl](meth)acrylamide, N-[2-(3,4-dihydroxyphenyl)ethyl](meth)acrylamide, N-[2-(3,4-dihydroxyphenyl)propyl](meth)acrylamide, N-[2-(3,4-dihydroxyphenyl)butyl](meth)acrylamide, N-[2-(3,4-dihydroxyphenyl)pentyl](meth)acrylamide, and N-[2 -(3,4-dihydroxyphenyl)hexyl](meth)acrylamide, N-[2-(3,4-dihydroxyphenyl)heptyl](meth)acrylamide, N-[2-(3,4-dihydroxyphenyl)octyl](meth)acrylamide, N-[2-(3,4-dihydroxyphenyl)nonyl](meth)acrylamide, N-[2-(3,4-dihydroxyphenyl)decyl](meth)acrylamide, N-[2-(3,4,5-trihydroxyphenyl)hexyl](meth)acrylamide

[0111] N-[2-(3,4,5-trihydroxyphenyl)methyl](meth)acrylamide, N-[2-(3,4,5-trihydroxyphenyl)ethyl](meth)acrylamide, N-[2-(3,4,5-trihydroxyphenyl)propyl](meth)acrylamide, N-[2-(3,4,5-trihydroxyphenyl)butyl](meth)acrylamide, N-[2-(3,4,5-trihydroxyphenyl)pentyl](meth)acrylamide, N-[2-(3,4,5-trihydroxyphenyl)hexyl](meth)acrylamide, N-[2-(3,4,5-trihydroxyphenyl)heptyl](meth)acrylamide, N-[2-(3,4,5-trihydroxyphenyl)octyl](meth)acrylamide, N-[2-(3,4,5-trihydroxyphenyl)nonyl](meth)acrylamide, N-[2-(3,4,5-trihydroxyphenyl)decyl](meth)acrylamide, and the like.

[0015] When L is an ester bond, the monomer represented by formula (1) is preferably a (meth)acrylic acid ester. Examples thereof include (meth)acrylic acid-2-(3,4-dihydroxyphenyl)methyl ester, (meth)acrylic acid-2-(3,4-dihydroxyphenyl)ethyl ester, (meth)acrylic acid-2-(3,4-dihydroxyphenyl)propyl ester, (meth)acrylic acid-2-(3,4-dihydroxyphenyl)butyl ester, (meth)acrylic acid-2-(3,4-dihydroxyphenyl)pentyl ester, (meth)acrylic acid-2-(3,4-dihydroxyphenyl)hexyl ester, (meth)acrylic acid-2-(3,4-dihydroxyphenyl)heptyl ester, (meth)acrylic acid-2-(3,4-dihydroxyphenyl)octyl ester, (meth)acrylic acid-2-(3,4-dihydroxyphenyl)nonyl ester, (meth)acrylic acid-2-(3,4-dihydroxyphenyl)decyl ester, (meth)acrylic acid-2-(3, (meth)acrylic acid-2-(3,4,5-trihydroxyphenyl)methyl ester, (meth)acrylic acid-2-(3,4,5-trihydroxyphenyl)ethyl ester, (meth)acrylic acid-2-(3,4,5-trihydroxyphenyl)propyl ester, (meth)acrylic acid-2-(3,4,5-trihydroxyphenyl)butyl ester, (meth)acrylic acid-2-(3,4,5-trihydroxyphenyl)pentyl ester, (meth)acrylic acid-2-(3,4,5-trihydroxyphenyl)hexyl ester, (meth)acrylic acid-2-(3,4,5-trihydroxyphenyl)heptyl ester, (meth)acrylic acid-2-(3,4,5-trihydroxyphenyl)octyl ester, (meth)acrylic acid-2-(3,4,5-trihydroxyphenyl)nonyl ester, and (meth)acrylic acid-2-(3,4,5-trihydroxyphenyl)decyl ester.

[0016] Furthermore, when L is a direct bond, examples of the monomer represented by formula (1) include 3,4-dihydroxystyrene, 3-(3,4-dihydroxyphenyl)-1-propene, 4-(3,4-dihydroxyphenyl)-1-butene, 5-(3,4-dihydroxyphenyl)-1-pentene, 6-(3,4-dihydroxyphenyl)-1-hexene, 7-(3,4-dihydroxyphenyl)-1-heptene, 8-(3,4-dihydroxyphenyl)-1-octene, 9-(3,4-dihydroxyphenyl)-1-nonene, 10-(3,4-dihydroxyphenyl)-1-propene, 11-(3,4-dihydroxyphenyl)-1-pentene, 12-(3,4-dihydroxyphenyl)-1-pentene, 13-(3,4-dihydroxyphenyl)-1-pentene, 14-(3,4-dihydroxyphenyl)-1-pentene, 15-(3,4-dihydroxyphenyl)-1-pentene, 16-(3,4-dihydroxyphenyl)-1-hexene, 17-(3,4-dihydroxyphenyl)-1-heptene, 18-(3,4-dihydroxyphenyl)-1-octene, 19-(3,4-dihydroxyphenyl)-1-nonene, 20-(3,4-dihydroxyphenyl)-1-pentene, 21-(3,4-dihydroxyphenyl)-1-pentene, 22-(3,4-dihydroxyphenyl)-1-pentene, 23-(3,4-dihydroxyphenyl)-1-pentene, 24-(3,4-dihydroxyphenyl)-1-pentene, 25-(3,4-dihydroxyphenyl)-1-pentene, 26-(3,4-dihydroxyphenyl)-1-pentene, 27-(3,4-dihydroxyphenyl)-1-pentene, 28-(3,4-di (3,4-dihydroxyphenyl)-1-decene, 3-(3,4-dihydroxyphenyl)-2-methyl-1-propene, 4-(3,4-dihydroxyphenyl)-2-methyl-1-butene, 5-(3,4-dihydroxyphenyl)-2-methyl-1-pentene, 6-(3,4-dihydroxyphenyl)-2-methyl-1-hexene, 7-(3,4-dihydroxyphenyl)-2-methyl-1-heptene, 8-(3,4-dihydroxyphenyl)-2-methyl-1-octene, 9-(3,4-dihydroxyphenyl)-2-methyl-1-nonene, 10-(3,4-dihydroxyphenyl)-2-methyl-1-pentene, (3,4,5-trihydroxyphenyl)-2-methyl-1-decene, 3,4,5-trihydroxystyrene, 3-(3,4,5-trihydroxyphenyl)-1-propene, 4-(3,4,5-trihydroxyphenyl)-1-butene, 5-(3,4,5-trihydroxyphenyl)-1-pentene, 6-(3,4,5-trihydroxyphenyl)-1-hexene, 7-(3,4,5-trihydroxyphenyl)-1-heptene, 8-(3,4,5-trihydroxyphenyl)-1-octene, 9-(3,4,5-trihydroxyphenyl)-1-nonene, 1 0-(3,4,5-trihydroxyphenyl)-1-decene, 3-(3,4,5-trihydroxyphenyl)-2-methyl-1-propene, 4-(3,4,5-trihydroxyphenyl)-2-methyl-1-butene, 5-(3,4,5-trihydroxyphenyl)-2-methyl-1-pentene, 6-(3,4,5-trihydroxyphenyl)-2-methyl-1-hexene, 7-(3,4,5-trihydroxyphenyl)-2-methyl-1-heptene, 8-(3,4,5-trihydroxyphenyl)-2-methyl-1-octene, 9-(3,4,5-trihydroxyphenyl)-2-methyl-1-nonene, 10-(3,4,5-trihydroxyphenyl)-2-methyl-1-decene, etc.

[0017] Among these, as the monomer represented by formula (1), N-[2-(3,4-dihydroxyphenyl)ethyl]methacrylamide (formula (3) below) or methacrylic acid-2-(3,4-dihydroxyphenyl)ethyl ester (formula (4) below) are preferred due to their ease of availability. Furthermore, methacrylic acid-2-(3,4-dihydroxyphenyl)ethyl ester is more preferred. Hydroxytyrosol, the raw material for methacrylic acid-2-(3,4-dihydroxyphenyl)ethyl ester, is a substance used as a supplement raw material and can be produced by plant extraction or biosynthesis.

[0018]

[0019]

[0020] As the (meth)acrylate monomer having a hydrophilic group, it is preferable to use at least one of (meth)acrylate monomers having a hydrophilic group such as a carboxy group, a hydroxy group, a sulfonate ion, or an ammonium ion.

[0021] Examples of (meth)acrylate monomers having a carboxy group include (meth)acrylic acid.

[0022] Examples of the (meth)acrylate monomer having a hydroxy group include 2-hydroxyethyl (meth)acrylate and 2-hydroxypropyl (meth)acrylate.

[0023] Examples of the (meth)acrylate monomer having a sulfonate ion include 3-sulfopropyl(meth)acrylate potassium salt.

[0024] Examples of the (meth)acrylate monomer having an ammonium ion include (meth)acryloylcholine chloride and 3-[[2-((meth)acryloyloxy)ethyl]dimethylammonio]propionate.

[0025] As the (meth)acrylate monomer having a hydrophilic group, a (meth)acrylate monomer having a hydroxy group represented by the following formula (2) is preferred. (In the formula, R 2 represents a hydrogen atom or a methyl group, and z represents an integer of 1 to 10.

[0026] In formula (2), R 2 represents a hydrogen atom or a methyl group; z represents an integer of 1 to 10, preferably an integer of 1 to 5, and more preferably an integer of 1 to 3.

[0027] From the viewpoint of improving adhesiveness to wet tissues, the constituent ratio of the monomer represented by formula (1) is preferably 0.01 mol% or more, more preferably 0.1 mol% or more, and even more preferably 1 mol% or more, based on the entire copolymer. Furthermore, from the viewpoint of solubility in solvents, it is preferably 30 mol% or less, more preferably 20 mol% or less, even more preferably 15 mol% or less, and particularly preferably 10 mol% or less. If the constituent ratio of the monomer represented by formula (1) is too low, sufficient adhesive performance tends to be insufficient for wet materials (especially biological tissues). Furthermore, if the constituent ratio of the monomer represented by formula (1) is too high, the solubility in solvents decreases, forcing the solids concentration in the polymer composition to be lowered, making it difficult to exhibit adhesive performance.

[0028] From the viewpoint of improving adhesiveness, the weight-average molecular weight of the copolymer is preferably 50,000 or more, more preferably 100,000 or more, and even more preferably 150,000 or more. Furthermore, from the viewpoint of solubility in solvents, it is preferably 500,000 or less, more preferably 400,000 or less, and even more preferably 300,000 or less. If the weight-average molecular weight is too small, the mechanical strength of the copolymer decreases, resulting in reduced adhesive strength and tissue bonding, and insufficient adhesive performance. Furthermore, if the weight-average molecular weight is too large, the solubility in solvents decreases, forcing the solids concentration in the polymer composition to be lowered, making it difficult to demonstrate adhesive performance.

[0029] The polymerization method for the copolymer is not particularly limited, and various known methods can be used for polymerization. For example, the monomer represented by formula (1), a (meth)acrylate monomer having a hydrophilic group, and other monomers can be dissolved in an organic solvent, a polymerization initiator can be added, and the resulting mixture can be polymerized by heating or light irradiation, for example.

[0030] Examples of organic solvents that can be used in the polymerization of the copolymer include N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), N,N-dimethylacetamide (DMAc), N-methylpyrrolidone (NMP), 1,4-dioxane, toluene, xylene, hexane, heptane, ethyl acetate, etc. Since this will be used for medical purposes, dimethyl sulfoxide, which has a proven track record of use in pharmaceuticals, is preferred.

[0031] As the polymerization initiator, it is preferable to use, for example, an azo compound such as 2,2'-azobisbutyronitrile (AIBN) or a peroxide such as benzoyl peroxide (BPO).

[0032] The solvent is preferably at least one selected from alcohols, ketones, ethers, esters, amides, sulfur compounds, chlorine compounds, aliphatic hydrocarbons, and aromatic hydrocarbons.

[0033] Examples of alcohols include methanol, ethanol, isopropanol, and glycerol. Examples of ketones include acetone, methyl ethyl ketone, and diethyl ketone. Examples of ethers include tetrahydrofuran and diethyl ether. Examples of esters include ethyl acetate and butyl acetate. Examples of amides include dimethylformamide, dimethylacetamide, and N-methylpyrrolidone. Examples of sulfur compounds include dimethyl sulfoxide and sulfolane. Examples of chlorine compounds include methylene chloride, trichloroethylene, and perchloroethylene. Examples of aliphatic hydrocarbons include hexane and cyclohexane. Examples of aromatic hydrocarbons include toluene and xylene.

[0034] Among the above solvents, at least one selected from the group consisting of alcohol and dimethyl sulfoxide is more preferred, and alcohol is even more preferred, as it can be used for medical purposes.

[0035] The solids concentration of the polymer composition used in the present invention, i.e., the concentration of the copolymer, is more preferably 5% by mass or more, and even more preferably 10% by mass or more, from the viewpoint of curing time. It may also be 20% by mass or more, or even 25% by mass or more. From the viewpoint of solubility in solvents, it is preferably 40% by mass or less, and more preferably 35% by mass or less. If the solids concentration is too low, curing takes a long time, and it tends to be difficult to exhibit adhesive performance. If the solids concentration is too high, it tends to be difficult to exhibit adhesive performance, as it tends to be difficult to exhibit solubility in solvents.

[0036] Examples of medical substrates include biological tissue, polyester, polyolefin, polyurethane, polyamide, fluororesin, and silicone. From the viewpoint of ensuring the curing of the polymer composition, the medical substrate is preferably a hydrated body, and more preferably a soft tissue in a moist state in a living body. The biological tissue and soft tissue used as the medical substrate may be derived from humans or non-human organisms, such as fish, amphibians, reptiles, birds, and non-human mammals (e.g., cows, sheep, horses, pigs, mice, rats, guinea pigs, hamsters, dogs, cats, and rabbits).

[0037] The polymer composition can be cured by contacting the polymer composition layer with the water-containing medium within 5 minutes from the time when the formation of the polymer composition layer is completed. In practice, since curing within a short period of time is required, contacting the polymer composition with the water-containing medium within 3 minutes is more preferable, and contacting the polymer composition with the water-containing medium within 1 minute is even more preferable.

[0038] The aqueous medium to be brought into contact with the polymer composition layer may be water alone, an aqueous solution containing salt and / or alcohol, or a body fluid. For example, an aqueous solution containing salt may be physiological saline. Examples of aqueous solutions containing alcohol include an aqueous ethanol solution and an aqueous isopropanol solution. The alcohol concentration is preferably 50% by volume or less, with the total volume of the aqueous medium being 100% by volume. In order to balance the promotion of curing inside the polymer composition layer and the shortening of the curing time of the entire polymer composition layer, the alcohol concentration is more preferably 30% by volume or less, and even more preferably 15% by volume or less, with the total volume of the aqueous medium being 100% by volume. Examples of body fluids include, but are not limited to, blood, interstitial fluid, lymphatic fluid, digestive fluid, and body cavity fluid.

[0039] The method for contacting the polymer composition layer with the water-containing medium is not particularly limited, and examples thereof include brushing, dripping, spraying, atomizing, and immersion. Alternatively, a porous material such as a sponge or cloth impregnated with the water-containing medium may be contacted. A combination of these methods may also be used.

[0040] The present invention will be explained in more detail below with reference to examples. The present invention is not limited to the following examples, and modifications can of course be made within the scope of the above and below-described aims, and all such modifications are included within the technical scope of the present invention. Evaluations in the examples and comparative examples were carried out as follows.

[0041] <Evaluation of Polymer Composition Hardening> As shown in Figure 1, two 1 cm square pieces of pig skin were placed side by side, and a polymer composition was applied to the joint of the pig skin to form a polymer composition layer. Next, the hardening state was evaluated by dropping a water-containing medium onto the polymer composition layer using a dropper. The time of contact with the solution was measured starting from the time when application was completed. Whether or not the polymer composition had hardened was confirmed by pulling both ends of the two pieces of pig skin and checking whether or not they could be joined. If the hardening was insufficient, the polymer composition could not be joined.

[0042] Synthesis Example 1 (Polymer Synthesis) Under a nitrogen atmosphere, 1.74 g (13.4 mmol) of 2-hydroxyethyl methacrylate (HEMA), 0.37 g (1.7 mmol) of methacrylic acid-2-(3,4-dihydroxyphenyl)ethyl ester (MMA-HT), 6.31 g of N,N-dimethylformamide (DMF), and 0.01 g (0.06 mmol) of azobisisobutyronitrile (AIBN) were placed in a 30 ml recovery flask, and the mixture was reacted at 65° C. for 19 hours to produce a copolymer. 1 The ratio of 2-hydroxyethyl groups to catechol groups determined by H-NMR was 10 / 90 (molar ratio).

[0043] Synthesis Example 2 (Polymer Synthesis) In a nitrogen atmosphere, 3.91 g (30.0 mmol) of HEMA, 11.71 g of DMF, and 0.05 g (0.3 mmol) of AIBN were placed in a 30 ml recovery flask and reacted at 60° C. for 28 hours to produce a homopolymer.

[0044] Example 1 A copolymer composition was prepared using the copolymer obtained in Synthesis Example 1 and mixing with ethanol so that the solids concentration was 32% by mass. This was applied to pig skin, and after 3 minutes, physiological saline was contacted. Whether or not it had hardened was confirmed 1 minute after contact. The results are shown in Table 1.

[0045] Example 2 A copolymer composition was prepared using the copolymer obtained in Synthesis Example 1 and mixed with isopropanol to give a solids concentration of 32% by mass. This was applied to pig skin, and after 3 minutes, a 15% by volume aqueous ethanol solution was contacted. One minute after contact, whether or not the composition had cured was confirmed. The results are shown in Table 1.

[0046] Example 3 A copolymer polymer composition was prepared in the same manner as in Example 1. This was applied to pig skin, and after 5 minutes, a 40% by volume aqueous ethanol solution was brought into contact with the composition. One minute after the contact, it was checked whether or not the composition had hardened. The results are shown in Table 1.

[0047] Example 4 A copolymer polymer composition was prepared in the same manner as in Example 1. This was applied to pig skin, and after 10 minutes, physiological saline was contacted. One minute after contact, it was confirmed whether or not it had hardened. The results are shown in Table 1.

[0048] Comparative Example 1 A copolymer polymer composition was prepared in the same manner as in Example 1. This was applied to pig skin, and after 3 minutes, acetone was brought into contact with the composition. One minute after contact, it was checked whether or not the composition had hardened. The results are shown in Table 1.

[0049] Comparative Example 2 A copolymer polymer composition was prepared in the same manner as in Example 1. This was applied to pig skin, and then the solution was not allowed to come into contact with the composition. Five minutes after application was complete, the composition was checked for hardening. The results are shown in Table 1.

[0050] Comparative Example 3 A copolymer composition was prepared using the copolymer obtained in Synthesis Example 2 and mixing with ethanol so that the solids concentration was 32% by mass. This was applied to pig skin, and after 3 minutes, physiological saline was contacted. Whether or not it had hardened was confirmed 1 minute after contact. The results are shown in Table 1.

[0051]

[0052] The method for curing a polymer composition of the present invention is capable of curing a polymer composition having high adhesiveness to medical substrates, particularly to materials in a wet state, without involving heating or irradiation with actinic rays, which may have adverse effects on the medical substrate, and is therefore expected to make a significant contribution to various medical applications.

[0053] The present invention provides the following aspects: [1] A method for curing a polymer composition, comprising: applying a polymer composition containing a solvent and a copolymer having, as constituent components, a monomer represented by the following formula (1) and a (meth)acrylate monomer having a hydrophilic group, to a medical substrate to form a polymer composition layer; and contacting the polymer composition layer with a water-containing medium to form a cured polymer composition layer. (In the formula, R 1represents a hydrogen atom or a methyl group, L represents an amide bond, an ester bond, or a direct bond, x represents 0 or an integer of 1 to 10, and y represents an integer of 1 to 5.) [2] The method for curing a polymer composition according to [1], wherein the solvent is an alcohol. [3] The method for curing a polymer composition according to [1] or [2], wherein the water-containing medium is either an aqueous solution containing at least one selected from the group consisting of table salt and alcohol, or a body fluid, or a mixture thereof. [4] The method for curing a polymer composition according to any of [1] to [3], wherein the medical substrate is a water-containing body. [5] The method for curing a polymer composition according to any of [1] to [4], wherein the medical substrate is derived from an organism other than a human. [6] The method for curing a polymer composition according to any of [1] to [5], wherein the water-containing medium is brought into contact with the polymer composition layer within 5 minutes after forming the polymer composition layer.

[0054] 1. Pig skin (1 piece, 1 cm square) 2. Pig skin joint 3. Polymer composition layer 4. Dropper 5. Water-containing medium 6. Tweezers 7. Cured polymer composition layer

Claims

1. A method for curing a polymer composition, comprising: applying a polymer composition containing a solvent and a copolymer having as its constituent components a monomer represented by the following formula (1) and a (meth)acrylate monomer having a hydrophilic group to a medical substrate to form a polymer composition layer; and contacting the polymer composition layer with a water-containing medium to form a cured polymer composition layer. (In the formula, R 1 represents a hydrogen atom or a methyl group, L represents an amide bond, an ester bond or a direct bond, x represents 0 or an integer of 1 to 10, and y represents an integer of 1 to 5.

2. A method for curing a polymer composition according to claim 1, wherein the solvent is an alcohol.

3. The method for curing a polymer composition according to claim 1 or 2, wherein the water-containing medium is either an aqueous solution containing at least one selected from the group consisting of table salt and alcohol, or a body fluid, or a mixture thereof.

4. The method for curing a polymer composition according to claim 1 or 2, wherein the medical substrate is a water-containing body.

5. The method for curing the polymer composition according to claim 1 or 2, wherein the medical substrate is derived from an organism other than a human.

6. The method for curing a polymer composition according to claim 1 or 2, wherein the polymer composition layer is contacted with the water-containing medium within 5 minutes after the polymer composition layer is formed.

Citation Information

Patent Citations

  • Compressor and Chiller including the same

    KR1020210093663A

Cited By

  • Polymer composition and medical adhesive containing same

    WO2025205896A1